Arcus Biosciences, Inc. (RCUS) Financial Statements (2026 and earlier)

Company Profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments978,000759,0001,009,000499,308173,41557,937
Cash and cash equivalent150,000127,000206,000147,914173,41557,937
Short-term investments828,000632,000803,000351,394  
Receivables5,0004,0004,0002,2271,592 
Contract with customer, asset, after allowance for credit loss20,00038,00039,000744,5951,049132
Other undisclosed current assets13,00030,00015,00015,620559,759134,636
Total current assets:1,016,000831,0001,067,0001,261,750735,815192,705
Noncurrent Assets
Operating lease, right-of-use asset    104,96812,781 
Property, plant and equipment47,00051,00035,00032,45510,8079,330
Long-term investments and receivables14,000107,000129,000181,9906,440 
Long-term investments14,000107,000129,000181,9906,440 
Restricted cash and investments    3,005203203
Other noncurrent assets73,000106,000114,0007,7306,246872
Total noncurrent assets:134,000264,000278,000330,14836,47710,405
TOTAL ASSETS:1,150,0001,095,0001,345,0001,591,898772,292203,110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,00017,00020,00052,90533,85714,226
Taxes payable1,815  
Employee-related liabilities16,6488,632 
Accounts payable18,00017,00020,00010,26115,6824,704
Accrued liabilities    24,1819,5439,522
Deferred revenue85,00091,00097,000102,00374,5717,000
Other liabilities123,00076,00076,000523,5661,480
Other undisclosed current liabilities    11,1249,675 
Total current liabilities:226,000184,000193,000166,084121,66922,706
Noncurrent Liabilities
Long-term debt and lease obligation:    116,88715,243 
Liabilities, other than long-term debt391,000449,000495,000467,477133,07616,562
Deferred revenue234,000307,000355,000462,217122,83012,022
Deferred rent credit      3,734
Other liabilities157,000142,000140,0005,26010,246806
Operating lease, liability    116,88715,243 
Total noncurrent liabilities:391,000449,000495,000584,364148,31916,562
Total liabilities:617,000633,000688,000750,448269,98839,268
Equity
Equity, attributable to parent485,000462,000657,000841,450502,304163,842
Common stock1,617,0001,311,0001,206,000764
Additional paid in capital    1,118,058830,438369,100
Accumulated other comprehensive income (loss)   (7,000)(1,261)4464
Accumulated deficit(1,132,000)(849,000)(542,000)(275,354)(328,184)(205,326)
Total equity:485,000462,000657,000841,450502,304163,842
Other undisclosed liabilities and equity48,000     
TOTAL LIABILITIES AND EQUITY:1,150,0001,095,0001,345,0001,591,898772,292203,110

Income Statement (P&L) ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues258,000117,000112,000382,88277,51715,000
Gross profit:258,000117,000112,000382,88277,51715,000
Operating expenses(588,000)(457,000)(392,000)(328,634)(201,752)(103,709)
Operating income (loss):(330,000)(340,000)(280,000)54,248(124,235)(88,709)
Nonoperating income48,00039,00014,0003971,3773,999
Interest and debt expense(4,000)     
Income (loss) from continuing operations before equity method investments, income taxes:(286,000)(301,000)(266,000)54,645(122,858)(84,710)
Loss from equity method investments     (613) 
Other undisclosed income from continuing operations before income taxes4,000     
Income (loss) from continuing operations before income taxes:(282,000)(301,000)(266,000)54,645(123,471)(84,710)
Income tax expense (1,000)(6,000)(1,000)(1,815)  
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(283,000)(307,000)(267,000)52,830(123,471)(84,710)
Income (loss) before gain (loss) on sale of properties:52,830(123,471)(84,710)
Other undisclosed net income     613 
Net income (loss) available to common stockholders, diluted:(283,000)(307,000)(267,000)52,830(122,858)(84,710)

Comprehensive Income ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(283,000)(307,000)(267,000)52,830(122,858)(84,710)
Other comprehensive income (loss)  7,000(6,000)(1,305)(20)171
Comprehensive income (loss):(283,000)(300,000)(273,000)51,525(122,878)(84,539)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive income (loss), net of tax, attributable to parent:(283,000)(300,000)(273,000)51,525(122,878)(84,539)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: